Kiniksa Pharmaceuticals International, plc (KNSA)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M, up 60.1% from the prior year. The company was profitable, with a net margin of 8.7%. It held $763.63M in total assets against $196.03M in total liabilities.
Key ratios (FY2025)
11.4%
Operating margin
8.7%
Net margin
10.4%
Return on equity
+60.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | — | — | — | — | — |
| Cost of Revenue | $77.67M | $60.91M | $33.41M | $22.89M | $9.10M | — | — | — | — | — |
| Operating Income | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M | -$157.36M | -$169.96M | -$108.16M | -$65.40M | — |
| Net Income | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M | -$161.38M | -$161.87M | -$103.23M | -$64.87M | — |
| EPS (Diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | — | — | — |
| Total Assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M | $349.46M | $254.53M | $321.96M | $47.49M | — |
| Total Liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M | $37.53M | $29.11M | $42.70M | $17.43M | — |
| Shareholders' Equity | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M | $311.94M | $225.42M | $279.27M | -$89.71M | -$25.73M |
| Cash & Equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M | $114.04M | $46.93M | $71.98M | $45.55M | — |
| Operating Cash Flow | $137.99M | $25.69M | $13.30M | $5.81M | -$126.30M | -$136.53M | -$158.37M | -$81.01M | -$50.22M | — |
| Capital Expenditures | $1.57M | $277.0K | $130.0K | $105.0K | $415.0K | $283.0K | $3.20M | $5.29M | $69.0K | — |
| Shares Outstanding | 78.98M | 71.42M | 71.92M | 70.42M | 68.58M | 61.84M | 54.05M | — | — | — |